Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1971 2
1977 1
1978 1
1980 1
1982 2
1983 5
1984 1
1985 5
1987 4
1988 3
1989 5
1990 8
1991 7
1992 8
1993 5
1994 8
1995 6
1996 12
1997 18
1998 13
1999 22
2000 17
2001 18
2002 23
2003 31
2004 23
2005 26
2006 22
2007 32
2008 38
2009 58
2010 34
2011 71
2012 69
2013 58
2014 60
2015 75
2016 78
2017 71
2018 68
2019 89
2020 101
2021 103
2022 107
2023 102
2024 50

Text availability

Article attribute

Article type

Publication date

Search Results

1,392 results

Results by year

Filters applied: . Clear all
Page 1
CD19 CAR T-Cell Therapy in Autoimmune Disease - A Case Series with Follow-up.
Müller F, Taubmann J, Bucci L, Wilhelm A, Bergmann C, Völkl S, Aigner M, Rothe T, Minopoulou I, Tur C, Knitza J, Kharboutli S, Kretschmann S, Vasova I, Spoerl S, Reimann H, Munoz L, Gerlach RG, Schäfer S, Grieshaber-Bouyer R, Korganow AS, Farge-Bancel D, Mougiakakos D, Bozec A, Winkler T, Krönke G, Mackensen A, Schett G. Müller F, et al. N Engl J Med. 2024 Feb 22;390(8):687-700. doi: 10.1056/NEJMoa2308917. N Engl J Med. 2024. PMID: 38381673
BACKGROUND: Treatment for autoimmune diseases such as systemic lupus erythematosus (SLE), idiopathic inflammatory myositis, and systemic sclerosis often involves long-term immune suppression. Resetting aberrant autoimmunity in these diseases through deep depletion o …
BACKGROUND: Treatment for autoimmune diseases such as systemic lupus erythematosus (SLE), idiopathic inflammatory myositis, and systemic scl …
Sepsis-Induced Immunosuppression.
Torres LK, Pickkers P, van der Poll T. Torres LK, et al. Annu Rev Physiol. 2022 Feb 10;84:157-181. doi: 10.1146/annurev-physiol-061121-040214. Epub 2021 Oct 27. Annu Rev Physiol. 2022. PMID: 34705481 Review.
Finally, we describe future challenges and the need for a new treatment paradigm, integrating predictive enrichment with patient factors that may guide the future selection of tailored immunotherapy....
Finally, we describe future challenges and the need for a new treatment paradigm, integrating predictive enrichment with patient fact …
Future Projections in Thyroid Eye Disease.
Barbesino G, Salvi M, Freitag SK. Barbesino G, et al. J Clin Endocrinol Metab. 2022 Aug 8;107(Suppl_1):S47-S56. doi: 10.1210/clinem/dgac252. J Clin Endocrinol Metab. 2022. PMID: 36346684 Free PMC article. Review.
Recently, teprotumumab, an insulin-like growth factor 1 receptor (IGF-1R) inhibitor, has demonstrated significant improvement in proptosis, clinical activity score, diplopia, and quality of life in patients with active TED, with good tolerability. ...CONCLUSION: New, albei …
Recently, teprotumumab, an insulin-like growth factor 1 receptor (IGF-1R) inhibitor, has demonstrated significant improvement in proptosis, …
The TIM3/Gal9 signaling pathway: An emerging target for cancer immunotherapy.
Kandel S, Adhikary P, Li G, Cheng K. Kandel S, et al. Cancer Lett. 2021 Jul 10;510:67-78. doi: 10.1016/j.canlet.2021.04.011. Epub 2021 Apr 22. Cancer Lett. 2021. PMID: 33895262 Free PMC article.
In addition, we discuss the potential of using TIM3 and Gal9 as prognostic and predictive biomarkers in different cancers. An in-depth mechanistic understanding of the blockade of the TIM3/Gal9 signaling pathway in cancer could help in identifying patients who respond to t …
In addition, we discuss the potential of using TIM3 and Gal9 as prognostic and predictive biomarkers in different cancers. An in-dept …
Interleukin-8: A chemokine at the intersection of cancer plasticity, angiogenesis, and immune suppression.
Fousek K, Horn LA, Palena C. Fousek K, et al. Pharmacol Ther. 2021 Mar;219:107692. doi: 10.1016/j.pharmthera.2020.107692. Epub 2020 Sep 24. Pharmacol Ther. 2021. PMID: 32980444 Free PMC article. Review.
Further, IL-8 can increase tumor angiogenesis or recruit larger numbers of immunosuppressive cells to the tumor. Prognostically, observations in many tumor types show that patients with higher levels of IL-8 at baseline experience worse clinical outcomes. ...More recently, …
Further, IL-8 can increase tumor angiogenesis or recruit larger numbers of immunosuppressive cells to the tumor. Prognostically, observat …
The Platelet-to-Lymphocyte Ratio as an Inflammatory Marker in Rheumatic Diseases.
Gasparyan AY, Ayvazyan L, Mukanova U, Yessirkepov M, Kitas GD. Gasparyan AY, et al. Ann Lab Med. 2019 Jul;39(4):345-357. doi: 10.3343/alm.2019.39.4.345. Ann Lab Med. 2019. PMID: 30809980 Free PMC article. Review.
PLR has been extensively examined in neoplastic diseases accompanied by immune suppression and thrombosis, which can be predicted by combined blood cell counts and their ratios. Several large observational studies have demonstrated the value of shifts …
PLR has been extensively examined in neoplastic diseases accompanied by immune suppression and thrombosis, which can be pre …
PI3Kgamma is a molecular switch that controls immune suppression.
Kaneda MM, Messer KS, Ralainirina N, Li H, Leem CJ, Gorjestani S, Woo G, Nguyen AV, Figueiredo CC, Foubert P, Schmid MC, Pink M, Winkler DG, Rausch M, Palombella VJ, Kutok J, McGovern K, Frazer KA, Wu X, Karin M, Sasik R, Cohen EE, Varner JA. Kaneda MM, et al. Nature. 2016 Nov 17;539(7629):437-442. doi: 10.1038/nature19834. Epub 2016 Sep 19. Nature. 2016. PMID: 27642729 Free PMC article.
In response to pathogens or injury, inflammatory macrophages express cytokines that stimulate cytotoxic T cells, whereas macrophages in neoplastic and parasitic diseases express anti-inflammatory cytokines that induce immune suppression and may promote resistance to …
In response to pathogens or injury, inflammatory macrophages express cytokines that stimulate cytotoxic T cells, whereas macrophages in neop …
The ecology of the microbiome: Networks, competition, and stability.
Coyte KZ, Schluter J, Foster KR. Coyte KZ, et al. Science. 2015 Nov 6;350(6261):663-6. doi: 10.1126/science.aad2602. Science. 2015. PMID: 26542567
We have analyzed host mechanisms for maintaining stability-including immune suppression, spatial structuring, and feeding of community members-and support our key predictions with recent data....
We have analyzed host mechanisms for maintaining stability-including immune suppression, spatial structuring, and feeding of c …
YKT6, as a potential predictor of prognosis and immunotherapy response for oral squamous cell carcinoma, is related to cell invasion, metastasis, and CD8+ T cell infiltration.
Yang Z, Yan G, Zheng L, Gu W, Liu F, Chen W, Cui X, Wang Y, Yang Y, Chen X, Fu Y, Xu X. Yang Z, et al. Oncoimmunology. 2021 Jun 23;10(1):1938890. doi: 10.1080/2162402X.2021.1938890. Oncoimmunology. 2021. PMID: 34221701 Free PMC article.
Metastasis and immune suppression account for the poor prognosis of oral squamous cell carcinoma (OSCC). ...The aggressive and immune-inhibitory phenotypes showed YKT6 overexpression, and the effect of YKT6 on OSCC cell invasion and metastasis in vitro was observ …
Metastasis and immune suppression account for the poor prognosis of oral squamous cell carcinoma (OSCC). ...The aggressive and …
Tryptophan depletion sensitizes the AHR pathway by increasing AHR expression and GCN2/LAT1-mediated kynurenine uptake, and potentiates induction of regulatory T lymphocytes.
Solvay M, Holfelder P, Klaessens S, Pilotte L, Stroobant V, Lamy J, Naulaerts S, Spillier Q, Frédérick R, De Plaen E, Sers C, Opitz CA, Van den Eynde BJ, Zhu J. Solvay M, et al. J Immunother Cancer. 2023 Jun;11(6):e006728. doi: 10.1136/jitc-2023-006728. J Immunother Cancer. 2023. PMID: 37344101 Free PMC article.
BACKGROUND: Indoleamine 2,3-dioxygenase 1 (IDO1) and tryptophan-dioxygenase (TDO) are enzymes catabolizing the essential amino acid tryptophan into kynurenine. Expression of these enzymes is frequently observed in advanced-stage cancers and is associated with poor disease …
BACKGROUND: Indoleamine 2,3-dioxygenase 1 (IDO1) and tryptophan-dioxygenase (TDO) are enzymes catabolizing the essential amino acid tryptoph …
1,392 results